Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia.

Abstract

Congenital hyperinsulinism is a rare disease, but is the most frequent cause of persistent and severe hypoglycaemia in early childhood. Hypoglycaemia caused by excessive and dysregulated insulin secretion (hyperinsulinism) from disordered pancreatic β cells can often lead to irreversible brain damage with lifelong neurodisability. Although congenital hyperinsulinism has a genetic cause in a significant proportion (40%) of children, often being the result of mutations in the genes encoding the KATP channel (ABCC8 and KCNJ11), not all children have severe and persistent forms of the disease. In approximately half of those without a genetic mutation, hyperinsulinism may resolve, although timescales are unpredictable. From a histopathology perspective, congenital hyperinsulinism is broadly grouped into diffuse and focal forms, with surgical lesionectomy being the preferred choice of treatment in the latter. In contrast, in diffuse congenital hyperinsulinism, medical treatment is the best option if conservative management is safe and effective. In such cases, children receiving treatment with drugs, such as diazoxide and octreotide, should be monitored for side effects and for signs of reduction in disease severity. If hypoglycaemia is not safely managed by medical therapy, subtotal pancreatectomy may be required; however, persistent hypoglycaemia may continue after surgery and diabetes is an inevitable consequence in later life. It is important to recognize the negative cognitive impact of early-life hypoglycaemia which affects half of all children with congenital hyperinsulinism. Treatment options should be individualized to the child/young person with congenital hyperinsulinism, with full discussion regarding efficacy, side effects, outcomes and later life impact.

• Authors: I Banerjee, M Salomon-Estebanez, P Shah, J Nicholson, K E Cosgrove, M J Dunne
• Journal: Diabetic medicine : a journal of the British Diabetic Association (Diabet Med) Vol. 36 Issue 1 Pg. 9-21 (01 2019) ISSN: 1464-5491 [Electronic] England
• PMID: 30246418 (Publication Type: Journal Article, Review)
• Copyright: © 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

Chemical References

• Antihypertensive Agents
• Gastrointestinal Agents
• Potassium Channels, Inwardly Rectifying
• Sulfonylurea Receptors
• Glucagon
• Diazoxide

Topics

• Antihypertensive Agents (adverse effects, therapeutic use)
• Congenital Hyperinsulinism (complications, physiopathology, therapy)
• Diazoxide (adverse effects, therapeutic use)
• Gastrointestinal Agents (therapeutic use)
• Glucagon (therapeutic use)
• Humans
• Hypoglycemia (etiology, physiopathology, therapy)
• Pancreatectomy (methods)
• Potassium Channels, Inwardly Rectifying (genetics)
• Precision Medicine
• Sulfonylurea Receptors (drug effects, genetics)
• Treatment Outcome